Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets

Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

Zealand Pharma launches major US research hub in Cambridge, Massachusetts

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities

New diabetes drug UBT251 shows strong phase 2 results in China

Alkem Laboratories launches affordable semaglutide injection in India

Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors